These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14702781)

  • 21. Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease.
    Gordon JN; MacDonald TT
    Gut; 2005 Sep; 54(9):1213-5. PubMed ID: 16099787
    [No Abstract]   [Full Text] [Related]  

  • 22. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.
    Stronkhorst A; Radema S; Yong SL; Bijl H; ten Berge IJ; Tytgat GN; van Deventer SJ
    Gut; 1997 Mar; 40(3):320-7. PubMed ID: 9135519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease.
    Bamias G; Marini M; Moskaluk CA; Odashima M; Ross WG; Rivera-Nieves J; Cominelli F
    J Immunol; 2002 Nov; 169(9):5308-14. PubMed ID: 12391251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease.
    Colpaert S; Vastraelen K; Liu Z; Maerten P; Shen C; Penninckx F; Geboes K; Rutgeerts P; Ceuppens JL
    Eur Cytokine Netw; 2002; 13(4):431-7. PubMed ID: 12517728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A patient with severe Crohn's colitis responds to Faecal Microbiota Transplantation.
    Gordon H; Harbord M
    J Crohns Colitis; 2014 Mar; 8(3):256-7. PubMed ID: 24239403
    [No Abstract]   [Full Text] [Related]  

  • 27. Cytokines and mucosal inflammatory response in Crohn's disease.
    van Deventer SJ
    Eur J Surg; 1998 Dec; 164(12):897-901. PubMed ID: 10029384
    [No Abstract]   [Full Text] [Related]  

  • 28. Cytokine gene expression in intestinal tuberculosis and Crohn's disease.
    Pugazhendhi S; Jayakanthan K; Pulimood AB; Ramakrishna BS
    Int J Tuberc Lung Dis; 2013 May; 17(5):662-8. PubMed ID: 23575333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in the management of Crohn's disease.
    Caprilli R; Angelucci E; Clemente V
    Dig Liver Dis; 2008 Sep; 40(9):709-16. PubMed ID: 18430617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.
    Kugathasan S; Saubermann LJ; Smith L; Kou D; Itoh J; Binion DG; Levine AD; Blumberg RS; Fiocchi C
    Gut; 2007 Dec; 56(12):1696-705. PubMed ID: 17682002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease.
    Gutiérrez A; Scharl M; Sempere L; Holler E; Zapater P; Almenta I; González-Navajas JM; Such J; Wiest R; Rogler G; Francés R
    Gut; 2014 Feb; 63(2):272-80. PubMed ID: 23376290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease.
    Connor SJ; Paraskevopoulos N; Newman R; Cuan N; Hampartzoumian T; Lloyd AR; Grimm MC
    Gut; 2004 Sep; 53(9):1287-94. PubMed ID: 15306587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
    Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
    Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
    Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
    Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Remission of Crohn's disease after human immunodeficiency virus infection.
    James SP
    Gastroenterology; 1988 Dec; 95(6):1667-9. PubMed ID: 2903112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effector Th-1 cells with cytotoxic function in the intestinal lamina propria of patients with Crohn's disease.
    Mariani P; Bachetoni A; D'Alessandro M; Lomanto D; Mazzocchi P; Speranza V
    Dig Dis Sci; 2000 Oct; 45(10):2029-35. PubMed ID: 11117579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell vaccination in Crohn's disease: principles and presentation of the first two cases.
    Agnholt J; Kaltoft K; Jakobsen NO; Dahlerup JF
    Cytokines Cell Mol Ther; 2002; 7(3):117-23. PubMed ID: 12850811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease.
    Bell S; Kamm MA
    Lancet; 2000 Mar; 355(9207):858-60. PubMed ID: 10752696
    [No Abstract]   [Full Text] [Related]  

  • 40. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease.
    Mouser JF; Hyams JS
    Clin Ther; 1999 Jun; 21(6):932-42; discussion 931. PubMed ID: 10440618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.